. We first used unsorted cells to measure the levels of 324 sequence-validated human miRNAs and found that 137 miRNAs were expressed at reliably detectable levels (Fig. 1a) . We then compared the expression of these 137 miRNAs in marker-positive versus marker-negative prostate cancer cell populations and found that miR-34a (1p36.22) was prominently underexpressed in all CD44 + populations (Fig. 1a) , being expressed at < 3% of the level in the corresponding CD44 − cells (Fig. 1b) . The other two miR-34 family members, miR-34b and miR-34c (11q23.1), did not show consistent differences between CD44 + and CD44 − prostate cancer cells (not shown). Underexpression of miR-34a in CD44 + prostate cancer cells was more pronounced than that of let-7b (Fig. 1b) , a tumor-suppressive miRNA 6 and an important regulator of both normal and cancer stem cells 3, 4 . We also found that miR-34a was underexpressed in LAPC4 CD133 + (Fig. 1b) (Fig. 1c) . These results suggest that miR-34a is underexpressed in the CD44 + prostate cancer cells in both xenograft and primary tumors. The expression of miR-34a is regulated by p53, and miR-34a induces apoptosis, cell-cycle arrest or senescence when introduced into cancer cells [20] [21] [22] [23] [24] 31 . We found that the expression of miR-34a in ten normal human prostate (NHP) epithelial strains, immortalized (but nontumorigenic) NHP cells and prostate cancer cell lines correlated with
Cancer stem cells (CSCs), or tumor-initiating cells, are involved in tumor progression and metastasis 1 . MicroRNAs (miRNAs) regulate both normal stem cells and CSCs [2] [3] [4] [5] , and dysregulation of miRNAs has been implicated in tumorigenesis 6 . CSCs in many tumors-including cancers of the breast 7 , pancreas 8 , head and neck 9 , colon 10, 11 , small intestine 12 , liver 13 , stomach 14 , bladder 15 and ovary 16 -have been identified using the adhesion molecule CD44, either individually or in combination with other marker(s). Prostate CSCs with enhanced clonogenic 17 and tumor-initiating and metastatic 18, 19 capacities are enriched in the CD44 + cell population, but whether miRNAs regulate CD44 + prostate cancer cells and prostate cancer metastasis remains unclear. Here we show, through expression analysis, that miR-34a, a p53 target [20] [21] [22] [23] [24] , was underexpressed in CD44 + prostate cancer cells purified from xenograft and primary tumors. Enforced expression of miR-34a in bulk or purified CD44 + prostate cancer cells inhibited clonogenic expansion, tumor regeneration, and metastasis. In contrast, expression of miR-34a antagomirs in CD44 − prostate cancer cells promoted tumor development and metastasis. Systemically delivered miR-34a inhibited prostate cancer metastasis and extended survival of tumor-bearing mice. We identified and validated CD44 as a direct and functional target of miR-34a and found that CD44 knockdown phenocopied miR-34a overexpression in inhibiting prostate cancer regeneration and metastasis. Our study shows that miR-34a is a key negative regulator of CD44 + prostate cancer cells and establishes a strong rationale for developing miR-34a as a novel therapeutic agent against prostate CSCs.
Many human cancers contain CSCs, which possess an enhanced tumor-initiating capacity, can self-renew, partially recreate the cellular heterogeneity of the parental tumor, and seem to be generally more resistant than other cancer cells to conventional anticancer therapeutics. Because of these properties, CSCs have been linked to tumor recurrence and distant metastasis 1 . Consequently, it is essential to elucidate the signaling and regulatory mechanisms that are unique to CSCs in order to design CSC-specific therapies. To this end, we used quantitative RT-PCR (qRT-PCR) to compare the miRNA expression 25, 26 of CD44 + and CD44 − prostate cancer cells. The CD44 + prostate cancer cell population harbors tumor-initiating and metastatic cells 18, 19 17 , and the LAPC9 side population is also enriched in tumor-initiating cells 28 . We first used unsorted cells to measure the levels of 324 sequence-validated human miRNAs and found that 137 miRNAs were expressed at reliably detectable levels (Fig. 1a) . We then compared the expression of these 137 miRNAs in marker-positive versus marker-negative prostate cancer cell populations and found that miR-34a (1p36.22) was prominently underexpressed in all CD44 + populations (Fig. 1a) , being expressed at < 3% of the level in the corresponding CD44 − cells (Fig. 1b) . The other two miR-34 family members, miR-34b and miR-34c (11q23.1), did not show consistent differences between CD44 + and CD44 − prostate cancer cells (not shown). Underexpression of miR-34a in CD44 + prostate cancer cells was more pronounced than that of let-7b (Fig. 1b) , a tumor-suppressive miRNA 6 and an important regulator of both normal and cancer stem cells 3, 4 . We also found that miR-34a was underexpressed in LAPC4 CD133 + (Fig. 1b) 27, 29, 30 and compared the expression of miR-34a. CD44 + HPCa cells expressed miR-34a at levels ~25-70% of those in CD44 − cells from the same tumors (Fig. 1c) . These results suggest that miR-34a is underexpressed in the CD44 + prostate cancer cells in both xenograft and primary tumors.
The expression of miR-34a is regulated by p53, and miR-34a induces apoptosis, cell-cycle arrest or senescence when introduced into cancer cells [20] [21] [22] [23] [24] 31 . We found that the expression of miR-34a in ten normal human prostate (NHP) epithelial strains, immortalized (but nontumorigenic) NHP cells and prostate cancer cell lines correlated with
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 their p53 status ( Supplementary Fig. 1 and Supplementary Results). Transfection of synthetic miR-34a oligonucleotides (oligos), but not the negative control (NC) miRNA oligos, induced cell-cycle arrest, apoptosis or senescence in p53-mutant and p53-null prostate cancer cells (Supplementary Figs. 2 and 3 and Supplementary Results).
To determine whether miR-34a can inhibit tumor development, we manipulated miR-34a levels ( Supplementary Fig. 4 ) in a variety of prostate cancer cell types and then implanted the cells subcutaneously or orthotopically in the dorsal prostate in NOD-SCID mice (Fig. 1d,e and Supplementary Fig. 5 ). LAPC9 ( Fig. 1d and Supplementary Fig. 5a ) and HPCa58 (Fig. 1e) cells transfected with miR-34a produced significantly smaller tumors than the same cells transfected with miR-NC oligos. LAPC9 cells are androgen dependent, whereas HPCa58 cells were from an early-generation xenograft tumor (Supplementary Methods). miR-34a also inhibited the secondary transplantation of HPCa58 cells (Fig. 1e) . miR-34a showed similar tumor-inhibitory effects on androgen-dependent LAPC4 (Supplementary Fig. 5b ) and androgen-independent Du145 (Supplementary Fig. 5d ) and PPC-1 ( Supplementary Fig. 5g ) cells. As expected, miR-34a-transfected prostate cancer cells showed miR-34a levels at several orders of magnitude higher than cells with miR-NC (Supplementary Fig. 4a ). In contrast to freshly transfected cells, the residual tumors showed only a marginal or no increase in miR-34a levels ( Supplementary Fig. 4b ), suggesting that transfected mature miR-34a oligo were gradually lost in vivo and explaining why miR-34a-overexpressing prostate cancer cells still regenerated some tumors. To complement the oligo transfection studies, we also infected prostate cancer cells with lentiviral or retroviral vectors encoding pre-miR-34a ( Supplementary Fig. 1d ) before implantation. The viral vector-mediated overexpression of miR-34a also inhibited tumor regeneration of LAPC4 ( Supplementary Fig. 5c ), Du145 ( Supplementary Fig. 5e ,f), and LAPC9 (not shown) cells. Notably, LAPC9 and LAPC4 cells transfected with miR-34a oligos ( Supplementary Fig. 5a ,b) and Du145 cells infected with the MSCV-34a retroviral vectors (Supplementary Fig. 5e ) all developed fewer tumors compared to the corresponding controls (P < 0.01 for tumor incidence). Histological and immunohistochemical examination of tumor sections (Supplementary Fig. 6 ) showed increased necrotic areas and reduced Ki-67 + cells in miR-34a transfected tumors, which also showed increased expression of HP-1γ (a protein that is associated with cell-cycle arrest and senescence). These overexpression experiments in unfractionated prostate cancer cells show that miR-34a possesses strong tumor-inhibitory effects.
To evaluate whether miR-34a-mediated inhibition of tumor development might be due to an effect on the CSC populations, we performed tumor growth experiments using purified CD44 + or CD44 − prostate cancer cells that had been subjected to manipulation of miR-34a levels. When we infected purified CD44 + Du145 cells with lenti-34a, tumor regeneration was completely blocked in that tumor incidence was 10/10 for the lenti-ctl group, whereas the incidence for the lenti-34a group was 0/10 ( Fig. 1f) . When we transfected CD44 + LAPC9 cells with miR-NC or miR-34a oligos, tumor incidence was 7/7 and 1/8, respectively (P = 0.016), and the only tumor observed in the miR-34a group was much smaller (0.03 g versus the mean tumor weight of 0.5 g for the miR-NC group) (Fig. 1g) . Similarly, lenti-34a infection of CD44 + LAPC9 cells also inhibited tumor regeneration (tumor incidences for the lenti-ctl and lenti-34a groups were 7/7 and 2/7, respectively; P = 0.01) (Supplementary Fig. 5h) .
We also performed the opposite experiments by introducing an antisense inhibitor of miR-34a (that is, anti-34a or miR-34a antagomir) into purified CD44 − Du145 or LAPC9 cells, which are less tumorigenic than the corresponding CD44 + cells 18, 19 . The antagomir-transfected LAPC9 cells showed reduced endogenous miR-34a ( Supplementary  Fig. 4c ) and increased mRNA levels of CDK4 (Supplementary Fig. 4d ), a known miR-34a target 26 , validating the specificity of anti-34a. We observed that CD44 − Du145 cells transfected with anti-34a developed larger tumors than those with anti-NC oligos (0.2 g versus 0.05 g; P = 0.038) (Fig. 1h) , which we verified in a repeat experiment (Supplementary Fig. 5i) H P C a 6 6 H P C a 1 0 2 H P C a 6 5 H P C a 7 6 H P C a 7 9 H P C a 7 4 H P C a 7 8 H P C a 7 7 H P C a 6 0 H P C a 9 3 H P C a 7 2 H P C a 6 2 H P C a 8 0 H P C a 8 1 H P C a 8 7 H P C a 9 1 H P C a 9 8 H P C a 8 9 bulk LAPC9 cells transfected with anti-34a oligos generated larger orthotopic tumors than those with anti-NC oligos ( Fig. 1i and Supplementary Fig. 7a ). Anti-34a also promoted subcutaneous tumor growth in purified CD44 − LAPC9 cells (Supplementary Fig. 7b ).
Notably, in the two orthotopic LAPC9 tumor experiments ( Fig. 1i and Supplementary Fig. 7a ), we observed lung metastasis in 5/9 (56%; for anti-NC) and 8/11 (73%; for anti-34a) tumor-bearing mice, respectively. When we quantified the GFP-bright foci (≥1 mm 3 ) in the five anti-NC and eight anti-34a mouse lungs, the latter showed higher levels of metastasis ( Fig. 1j and Supplementary Fig. 7c,d ). Taken together, these in vivo experiments in purified prostate cancer cells suggest that miR-34a negatively regulates the tumor-initiating capacity of prostate CSCs.
To further investigate the effects of miR-34a on prostate CSC properties, we performed holoclone, clonogenic and sphere formation assays 18, 19, 27, 32, 33 . Prostate cancer cell holoclones contain selfrenewing cancer cells 32 , and sphere-formation assays have been widely used to measure the activity of stem or progenitor cells 1, 33 . We first established stringent competition assays in which clones (holoclones formed in culture dishes), colonies (formed in Matrigel or methylcellulose) and (floating) spheres were all of clonal origin ( Supplementary  Fig. 8 ). Under these conditions, miR-34a overexpression inhibited holoclone formation, clonogenic capacity, or sphere establishment in Du145 (Fig. 2a,b and Supplementary Fig. 2d,e) , LAPC4 (Fig. 2c,d ) and PPC-1 ( Fig. 2e and Supplementary Fig. 3h,i) cells. In addition, miR-34a inhibited sphere formation by primary HPCa cells (Fig. 2f and Supplementary Fig. 9a ). HPCa cells overexpressing miR-34a formed tiny or differentiated spheres (Supplementary Fig. 9b) . Notably, miR-34a overexpression abrogated secondary sphere establishment (Fig. 2d,f) and inhibited sphere formation in purified CD44 + HPCa116 cells (Fig. 2g) . By contrast, anti-34a increased the inherently low sphere-forming capacity of CD44 − HPCa116 cells several-fold (Fig. 2h) . These observations collectively indicate that miR-34a negatively regulates prostate CSC properties.
Subsequently, we performed four sets of therapeutic experiments ( Fig. 3 and Online Methods) in NOD-SCID mice with established prostate tumors. We first observed that repeated intratumoral injections of miR-34a into subcutaneous PPC-1 tumors halted tumor growth (Supplementary Fig. 5g ). We then established orthotopic PC3 tumors and, 3 weeks later, injected miR-34a or miR-NC oligos complexed with a lipid-based delivery agent 26 into the tail veins of mice every 2 d. Systemically delivered miR-34a reduced PC3 tumor burden by 50% (Fig. 3a) . In two therapeutic experiments with orthotopic LAPC9 tumors, miR-34a reduced lung metastasis (Fig. 3b,e,f and Supplementary Fig. 10 ) without affecting tumor growth (Fig. 3c) . miR-34a also extended the survival of tumor-bearing mice (Fig. 3d) . These results indicate that miR-34a has therapeutic efficacy against established prostate tumors.
Cyclin D1, CDK4 and 6, E2F3, N-Myc, c-MET and BCL-2 have been reported to be direct targets of miR-34a [20] [21] [22] [23] [24] 26, 31, 34, 35 . A survey of some of these molecules revealed that miR-34a affected the levels of cyclin D1, CDK4, CDK6 and c-MET in our prostate cancer models (Supplementary Figs. 4d,e and 6d,e) . There was a consistent and strong inverse correlation between miR-34a levels and CD44 (Fig. 4a,b, Supplementary Figs. 1a, 4e and 11a-c and Supplementary Table 2 ). For example, CD44 protein and CD44 + prostate cancer cells were reduced in miR-34a-treated tumors (Fig. 4a) . Transfected miR-34a downregulated CD44 in prostate cancer cells (Fig. 4b and Supplementary Fig. 11a,b) . By contrast, CD44 mRNA (Supplementary Fig. 4e) (Fig. 4c) . When we cloned the 3′ UTR fragment containing both putative miR-34a binding sites downstream of a luciferase coding sequence ( Supplementary Fig. 11d,e) , co-transfection of the luciferase reporter and miR-34a oligos into three prostate cancer cell types produced lower luciferase activity than in cells co-transfected with the NC oligos. However, mutation of the seed sequence in either site, especially the distal site, partially abrogated the suppressive effect of miR-34a ( Fig. 4d and Supplementary Fig. 11f,g ). These results suggest that miR-34a regulates CD44 expression through two binding sites in the 3′ UTR of the gene that encodes CD44. To determine whether CD44 is a functionally important target of miR-34a in the context of prostate cancer development, we reduced CD44 expression using a lentiviral vector carrying a short hairpin RNA (shRNA) against CD44 (Supplementary Fig. 1d ) in LAPC4, PC3 and Du145 cells. Knockdown of CD44 in LAPC4 cells inhibited both orthotopic tumor formation (Fig. 4e) and lung metastasis (Supplementary Fig. 12) . In PC3 cells, it markedly inhibited metastasis (Fig. 4f,g and Supplementary Fig. 13 ) without affecting tumor growth (data not shown). Knockdown of CD44 in Du145 cells inhibited tumor development in both subcutaneous and orthotopic sites (Supplementary Fig. 14a,b) as well as metastasis (not shown). These results not only show that CD44 has a key role in determining the tumorigenic and metastatic capacity of prostate cancer cells but also indicate that knockdown of CD44 phenocopies the anti-prostate cancer effects of miR-34a. Mechanistically, the CD44 + prostate cancer cells showed higher migratory (Supplementary Fig. 14c,d ) and invasive ( Supplementary Fig. 14e ) capacities than CD44 − cells, and these capacities were partially inhibited by miR-34a ( Fig. 4h and  Supplementary Fig. 14f,g ). 'Rescue' experiments wherein CD44 was overexpressed using a cDNA that lacked the 3′ UTR containing the miR-34a binding sites abrogated miR-34a-mediated inhibition of invasion of CD44 + Du145 cells (Fig. 4i) , reinforcing the idea that CD44 is a direct and functional target of miR-34a. By contrast, overexpression of CD44 did not significantly relieve the inhibition of prostate cancer cell proliferation by miR-34a (Supplementary Fig. 15) .
We have shown that miR-34a is underexpressed in tumorigenic CD44 + prostate cancer cells and that it has potent antitumor and antimetastasis effects. Our results establish miR-34a as a key negative regulator of CD44 + prostate cancer cells and CD44 as an important target of miR-34a. Our findings suggest that reduced expression of miR-34a in prostate CSCs contributes to prostate cancer development and metastasis by regulating expression of CD44 and the migratory, invasive and metastatic properties of CSCs (Fig. 4j) . It is noteworthy that p53, which directly activates miR-34a, also negatively regulates CD44 through a noncanonical p53-binding site in the promoter 37 . Considering the widespread expression of CD44 in CSCs [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and the functional involvement of CD44 in mediating CSC migration and homing 38 and in metastasis of many cancers, the suppression of CD44 by miR-34a reveals a previously unknown signaling pathway that regulates prostate CSCs (Fig. 4j) . The emerging role of miR-34a in regulating other CSC 35, 39 properties, coupled with the therapeutic effects of miR-34a on lung 26 and prostate tumors (this study), establishes a strong rationale for developing miR-34a as a therapeutic agent that targets prostate CSCs.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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